Skip to main content

Advertisement

Table 1 Population pharmacokinetic models and parameter values for the non-pregnant adults and pregnant women designs

From: Optimal designs for population pharmacokinetic studies of oral artesunate in patients with uncomplicated falciparum malaria

  Non-pregnant adults Pregnant women,
Model &Parameter* Estimate (95% CI) Estimate (95% CI) Estimate (95% CI)
Bateman model    
k a (/h) 0.82 (0.76, 0.87) 0.89 (0.81, 0.97) 1.19 (0.78, 1.60)
CL/F (L/h) 47.5 (44.6, 50.4) 48.8 (42.3, 55.3) 88.5 (60, 117)
V/F (L) 32.1 (24.6, 39.6) 44.4 (30.2, 58.6) 232 (57.0, 406)
t lag (h) 0.21 (fixed) n/a 0.42 (0.34, 0.50)
26.7 11.4 not reported
Ω CL / F 29.4 26.8 47.0
Ω V / F 81.9 64.7 154
10.0 n/a not reported
Ω CL / F , V / F 0.58 0.75 not reported
0.19 n/a not reported
σ 0.41 0.55 not reported
Dost model    
k (/h) 0.99 (0.91, 1.1) 0.95 (0.86, 1.03)  
V/F (L) 46.3 (37.6, 55.0) 51.3 (41.2, 61.4)  
t lag (h) 0.21 (fixed) n/a  
Ω k 22.0 20.8  
Ω V / F 48.2 42.2  
11.4 n/a  
Ω k , V / F -0.79 -0.81  
σ 0.47 0.57  
  1. *The Ω's represent between-subject variances and covariances, expressed as the percent coefficient of variation (%CV, approximated by the square root of the variance estimate multiplied by 100) and correlation coefficients, respectively
  2. §The σ's represent residual standard deviations (proportional)
  3. Taken from McGready et al. [5]
  4. Reported CL/F (L/kg/h) and V/F (L/kg) multiplied by median weight (50 kg)
  5. Lag-time included
  6. Lag-time not included
  7. Upper and lower bounds of CIs were considered for the PK parameters only